Baseline patient characteristics among stage III patients comprising the retrospective cohort

VaccineNo Adjuvant
N = 67N = 123
N(%)/Mean(SD)N(%)/Mean(SD)P-Value
Age56.00 (13.44)60.05 (16.44)0.086
Sex0.2854
 Female31 (46.27)47 (38.21)
 Male36 (53.73)76 (61.79)
Thicknessa3.12 (4.43)4.18 (4.46)0.009
Ulceration0.3511
 Present23 (34.33)52 (42.28)
 Absent32 (47.76)57 (46.34)
 Undetermined12 (17.91)14 (11.38)
AJCC Stage0.0082
 IIIA15 (22.39)48 (39.02)
 IIIB26 (38.81)51 (41.46)
 IIIC26 (38.81)24 (19.51)
Histologic Subtype0.0435
 Nodular17 (25.37)52 (42.28)
 Superficial Spreading12 (17.91)26 (21.14)
 Other6 (8.96)13 (10.57)
 Undetermined32 (47.76)32 (26.02)
Other Adjuvant Treatment
 GM-CSF6 (8.96)Not Applicable
 Interferon6 (8.96)
 Isolated Limb Infusion3 (4.48)
 Radiation22 (32.84)

amissing values for thickness: vaccine: 10; no adjuvant: 13

athickness not normally-distributed, log-transformed for statistical test